News >

ONT-380/T-DM1 Combo Shows Promise in HER2+ Breast Cancer With CNS Mets

Gina Columbus @ginacolumbusonc
Published: Monday, Mar 28, 2016

Erika P. Hamilton, MD

Erika P. Hamilton, MD

The combination of the oral HER2 inhibitor ONT-380 and T-DM1 (ado-trastuzumab emtansine; Kadcyla) has shown early evidence of clinical activity in patients with metastatic HER2-positive breast cancer with or without brain metastases, according to results of a phase Ib study.1

In the dose-escalation study, which was presented during the 2015 San Antonio Breast Cancer Symposium, patients with HER2-positive disease with or without brain metastases received ONT-380 combined with a 3-week treatment of T-DM1 at 3.6 mg/kg.

Results showed that, out of the 51 patients enrolled, the maximum tolerated dose was 300 mg twice daily, with 14% of patients having dose-limiting toxicities, including an elevation of liver enzymes (AST/ALT). Grade 1/2 events included vomiting and diarrhea. At the 350-mg dose, 43% of patients had dose-limiting toxicities, including grade 3 vomiting, hypersensitivity, and fatigue.

In 33 of 43 evaluable patients, the best systemic response, regardless of dose, was 11 partial responses, 16 patients with stable disease, and 6 with progressive disease. The clinical benefit rate was 58%.

Results of a second study,2 also presented during the meeting, specifically looked at the patients with brain metastases (n = 24) from the phase Ib research who received ONT-380 in combination with T-DM1, capecitabine, trastuzumab, or capecitabine and trastuzumab.

In the 14 evaluable patients who received one of the ONT-380 combinations, responses included 1 complete response (T-DM1), 4 partial responses (T-DM1, n = 2; trastuzumab + capecitabine, n = 1; capecitabine, n = 1), and 9 patients with stable disease (T-DM1, n = 5; trastuzumab, n = 3; trastuzumab + capecitabine, n = 1).

These findings demonstrate early clinical activity of ONT-380 with T-DM1 against HER2-positive disease with brain metastases.

In an interview with OncLive, Erika P. Hamilton, MD, the director of Breast Cancer and Gynecologic Research Program at Sarah Cannon Research Institute and an author on both studies, discusses the significance of these trials and the impact ONT-380 may have on the treatment paradigm of HER2-positive breast cancer.

OncLive: Can you give an overview of both studies examining ONT-380?

Hamilton: This is a novel HER2-specific inhibitor called ONT-380 made by a company named Oncothyreon. What is special about this drug is it is HER2-specific.

Most of our oral HER2 inhibitors block not only HER2, but also other proteins such as EGFR. Often, that is what translates to a lot of the toxicities, such as rash and diarrhea. What is special about this medicine is that it only blocks HER2, so it tends to be very tolerable in the patients who have had it thus far.

Additionally, it crosses into the blood-brain barrier. As we all know, brain metastases are a special problem for HER2-positive patients; up to 50% of HER2-positive patients will end up with brain metastases. This is much higher than patients with triple-negative or estrogen receptor¬–positive breast cancer.

The first study is an update with the T-DM1 combination with ONT-380. This is kind of in the second-line setting of HER2-positive metastatic breast cancer. The response rate is 41% in that, which is pretty encouraging. Not only are women responding, but also they are remaining on treatment for a long time. The clinical benefit rate is 59% in that study.

The second study is a combination of all of the women who have brain metastases from that T-DM1 combination trial. There is also their third-line study, which is capecitabine, trastuzumab and ONT-380.

What is particularly compelling there is how well the women with brain metastases did. The response rates are in the 33% to 38% range, and the clinical benefit is somewhere between 44% and 59%, depending on whether women had received local therapy to their brain lesions.

Oncothyreon is actually moving this drug into a phase II study. They’re going to take the triplet into trial first: capecitabine and trastuzumab versus capecitabine, trastuzumab, and ONT-380.

Are there any overlapping toxicities with the triplet?

There really isn’t. I think that’s the really attractive thing about ONT-380. It doesn’t cause the nausea and diarrhea like we see with some of the other medications. With capecitabine, patients can certainly have hand-foot syndrome, but that can be controlled with dose reductions. Capecitabine alone can also cause some diarrhea. Trastuzumab did not add any toxicity to the combination.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Publication Bottom Border
Border Publication
x